General Information
Version
7.0
Revision date
2021-05-06
Product name
N-[2-(Trifluoromethyl)phenyl]acetamide
CAS No.
344-62-7
REACH No
A
Emergency telephone
+(46)-852503403
Icons in SDS
Company Information
company name
Merck Life Science AB
e-mail address of the competent person responsible for the Safety Data Sheet
TechnicalService@merckgroup.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H302, H334
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008] Classification of the substance or mixture
Signal word
Danger Danger
Hazard statements
H302 Harmful if swallowed. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled. H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
Precautionary statements
P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P284 Wear respiratory protection. P301 + P312 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. Supplemental Hazard none Statements Reduced Labeling (<= 125 ml) P261 Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P284 Wear respiratory protection. P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.
Supplemental label elements
none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Oral (Category 4), H302 Respiratory sensitization (Category 1), H334 For the full text of the H-Statements mentioned in this Section, see Section 16.